Latest news with #CSU
Yahoo
4 days ago
- Business
- Yahoo
This Canadian Stock Could Be the Best Investment This Decade
Written by Amy Legate-Wolfe at The Motley Fool Canada When looking for the best Canadian stock to own this decade, the answer may not be a flashy newcomer or a trendy pick. It may just be one of the quietest, most consistent performers on the TSX. Constellation Software (TSX:CSU) isn't a household name for most Canadians, but it has built one of the strongest track records in Canadian market history. For long-term investors, this could be the stock to hold for the next 10 years and beyond. Constellation Software is a Toronto-based company that acquires and operates vertical market software businesses. That means it buys companies that serve specific industries, like software for libraries, police departments, or insurance brokers. These aren't high-growth social media apps or cloud platforms with huge hype. Instead, they're niche businesses that provide mission-critical services and generate reliable recurring revenue. And that's the secret to Constellation's success. The Canadian stock is now valued at around $104 billion and has grown consistently since going public in 2006. It operates through six major business units across North America, Europe, and Australia. Each division runs semi-independently, allowing local managers to focus on their customers while benefiting from the strength of the overall company. That decentralized model has allowed Constellation to scale without losing its grip on performance. In its most recent earnings report for the first quarter of 2025, Constellation reported revenue of US$2.7 billion, up 13% from the same period last year. Net income came in at US$115 million, up nearly 10%. Over the last 12 months, the company has generated $14.9 billion in revenue and $1.1 billion in net income. Those numbers are impressive for any company, let alone one that rarely makes headlines. The software firm is also incredibly efficient. Its return on equity is 26%, and its return on assets is 7.5%. Constellation is a cash machine, bringing in over $3.1 billion in free cash flow over the last year. It uses that cash to make more acquisitions, often small ones that fly under the radar but add meaningful long-term value. Unlike some Canadian stocks that make one big splashy deal, Constellation has made hundreds of small ones over the years. That strategy has worked exceptionally well. Yes, the Canadian stock trades at a high valuation. CSU's trailing price-to-earnings (P/E) ratio is around 97, and its forward P/E sits near 41. But this has never been a cheap stock, and it likely never will be. That's because investors are willing to pay up for the consistency, profitability, and long-term strategy. The Canadian stock has very little customer churn, very little debt pressure, and a clear path for continued growth. And in a world where many tech companies are still chasing profits, Constellation has delivered year after year. Analyst sentiment remains strong. Most experts have a buy or hold rating on the stock, with an average target price above $5,200. That's modest upside from current levels, but the real appeal here is the compound growth over time. It's not going to double overnight, but that's not the point. This is a long-term compounder, not a short-term trade. As Canadians tighten budgets due to rising mortgage costs and market uncertainty, it's more important than ever to focus on high-quality, dependable investments. In that kind of environment, owning a steady compounder like Constellation makes a lot of sense. Constellation Software may not get the same buzz as other tech names, but its results speak for themselves. It grows steadily, manages capital wisely, and serves industries that don't disappear in downturns. For anyone looking to invest in a Canadian stock that could define their portfolio over the next decade, CSU might be the one to watch. It's quietly magnificent, and exactly the kind of Canadian stock built to last. The post This Canadian Stock Could Be the Best Investment This Decade appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool recommends Constellation Software. The Motley Fool has a disclosure policy. 2025 Sign in to access your portfolio
Business Upturn
6 days ago
- Health
- Business Upturn
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 (150 mg Q4W) Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. The data were presented today by Dr. Martin Metz, Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin, in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 (weekly urticaria activity score) compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented today further support these results by demonstrating improvements in AAS7 (weekly angioedema activity score) and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity. 'The majority of patients with severe CSU suffer with angioedema, which is often extremely painful and causes disfigurement, dramatically impacting quality of life,' said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. 'Consistent with previously reported clinical outcomes, we observed rapid, profound angioedema relief with barzolvolimab treatment and this benefit continued to improve over 52 weeks of therapy for patients. These data add to the unprecedented 76 week efficacy and safety data we presented yesterday at EAACI and continue to support barzolvolimab's potential to redefine the treatment landscape and meet the goals of CSU therapy—rapid, profound, durable complete response and improved quality of life across a broad patient population.' Summary of Key Findings: Patients on study had severe CSU. Over 70% of patients had a weekly urticaria activity score (UAS7) greater than 28 at baseline and reported very high rates of angioedema at baseline. Barzolvolimab demonstrated rapid, robust and durable improvements in angioedema symptoms over the treatment period. At Week 52, an 86% mean reduction from baseline was reported for 150 mg Q4W arm and an 82% reduction was reported for the 300 mg Q8W. Up to 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema free (AAS7=0) at Week 52. Patients treated with barzolvolimab were angioedema free up to 72% of the time over the 52 week treatment period. Up to 87% of patients reported clinically meaningful improvement ( > 8 point) in AAS7 at Week 52. 1 DermNet . About Barzolvolimab Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU Study The randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients entered a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 Program Celldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU) CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit Forward Looking Statement This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under 'Risk Factors' in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337 [email protected]
Yahoo
7 days ago
- Health
- Yahoo
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. The data were presented today by Dr. Martin Metz, Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin, in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 (weekly urticaria activity score) compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented today further support these results by demonstrating improvements in AAS7 (weekly angioedema activity score) and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity. 'The majority of patients with severe CSU suffer with angioedema, which is often extremely painful and causes disfigurement, dramatically impacting quality of life,' said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. 'Consistent with previously reported clinical outcomes, we observed rapid, profound angioedema relief with barzolvolimab treatment and this benefit continued to improve over 52 weeks of therapy for patients. These data add to the unprecedented 76 week efficacy and safety data we presented yesterday at EAACI and continue to support barzolvolimab's potential to redefine the treatment landscape and meet the goals of CSU therapy—rapid, profound, durable complete response and improved quality of life across a broad patient population.' Summary of Key Findings: Patients on study had severe CSU. Over 70% of patients had a weekly urticaria activity score (UAS7) greater than 28 at baseline and reported very high rates of angioedema at baseline. Barzolvolimab demonstrated rapid, robust and durable improvements in angioedema symptoms over the treatment period. At Week 52, an 86% mean reduction from baseline was reported for 150 mg Q4W arm and an 82% reduction was reported for the 300 mg Q8W. Up to 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema free (AAS7=0) at Week 52. Patients treated with barzolvolimab were angioedema free up to 72% of the time over the 52 week treatment period. Up to 87% of patients reported clinically meaningful improvement (>8 point) in AAS7 at Week 52. 1DermNet. About BarzolvolimabBarzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU StudyThe randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients entered a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 ProgramCelldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU)CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit Forward Looking Statement This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337scavanaugh@ Patrick TillMeru Advisors(484) 788-8560ptill@ in to access your portfolio
The Sun
7 days ago
- Sport
- The Sun
WWE legend Brock Lesnar's daughter Mya makes history after winning NCAA national shot put title
BROCK LESNAR'S daughter Mya has reached new heights after setting a college record. The 23-year-old senior out of Colorado State threw 19.01 meters in the first round to win the NCAA shot put championship. 5 5 Since Loree Smith's 2005 victory in an outdoor event, she is the only Rams athlete to achieve so, and joins her former WWE star father in securing a national crown, with Brock, a heavyweight wrestler at Minnesota winning an NCAA title back in 2000. Mya, who had won the indoor championship in 2024, is keen to make her own way despite the talk around her famous dad. Mya's high throw of 62 feet, 4 1/2 inches was part of her incredible effort that helped seal the win. Every participant gets three chances, but Mya got an early edge by making a statement with a throw that exceeded 60 feet. At 61 feet, 10 1/4 inches, Illinois athlete Abria Smith's third throw put her in second place. Nevertheless, Mya easily won with her second-best throw of 61 feet, 11 inches. Her ecstatic father Brock watched from the stands as she would go on to keep the family name in the national rafters. The younger Lesnar earlier won the NCAA indoor shot put title in 2024, making him just the sixth Colorado State athlete to earn outdoor gold. Mya is now the only athlete in program history to win both indoor and outdoor championships. After transferring from Arizona State to CSU, Mya became one of the country's best collegiate throwers under coach Brian Bedard. She came into this week's competition as the top seed in the country after placing sixth at the 2024 Summer Olympics in Paris. Last summer, she would go on to win an Olympic bronze with her personal best score of 64 feet, 3 3/4 inches. "Heck yeah it was. It was pretty awesome," Lesnar said to the school's athletics website, on her triumph. "Obviously throws like that don't happen often, and to do it on my first one was pretty cool. I just went calm, hit my cues. [Rams coach Brian] Bedard and I have tons of trust, and that's exactly what we did." As stated, her achievements echoes her famous father. Brocl came back from a losing position in double overtime to win 3-2 in one of the most thrilling tournament finals ever. In addition to starting a career that would include celebrity status in the WWE, UFC, and a brief NFL stint, that victory culminated a 50-2 record at Minnesota. 5 5 His daughter's ascent to NCAA greatness now partially matches his remarkably powerful athletic past. Since his final in-ring performance at SummerSlam 2023, Brock has been absent from the professional wrestling industry.
Yahoo
14-06-2025
- Yahoo
Two dogs disappear, were found after being killed according to Larimer County family
LARIMER COUNTY, Colo. (KDVR) — A family that lives in a ranching area southwest of Berthoud said a necropsy they ordered indicates their dogs were killed. The Larimer County Sheriff's Office and NOCO Humane said they are investigating how the dogs died. Possible measles exposure locations in Denver, Boulder after new confirmed case It was Mother's Day when the family returned to their home on their ranch west of Berthoud, and they noticed their dogs were missing. The family quickly began looking for the two cherished pets. For days, family, friends and neighbors searched for the dogs, Kevin Jones and his family had come to love so much. Then both dogs were found dead weeks later, on different days, at a drain at the end of a two-mile-long canal nearby. 'The process has been truly devastating, and you know and it's kind of a ridiculous situation,' Jones said. The Jones family said they had a necropsy performed at CSU, which they said determined both dogs had died of blunt force trauma. Jones said he received a tip that a pickup truck was seen picking up the dogs along a road not far from the family's home. 'We don't typically see this kind of stuff out here. The community is very close-knit. We are friends with all our neighbors,' said Jones. The Jones family called the sheriff to say the dogs had disappeared under suspicious circumstances. 'The dogs' cause of death has not yet been determined. The investigation is ongoing in partnership with NOCO Humane,' a spokesperson for the Larimer County Sheriff's Office said. Both of the dogs' bodies are with NOCO Humane, according to the family. Both had collars and ID tags on them when they were found, but no one called to say they had Finnegan and Lucy. 'It's awful, I can't even imagine how that even happens. It's disgusting,' Jones said. The two had become like members of the Jones family. They were country dogs and roamed freely on the ranch, where they were loved so much. A community is now asking what happened to Finnegan and Lucy? Their family is hoping for answers soon. The Larimer County Sheriff's Office said it will continue to work to find answers in this case. Did you feel it? 2.9 magnitude earthquake recorded in Colorado Anyone with information is encouraged to contact Deputy Spencer at 970-498-5211. People who want to remain anonymous can also contact Crime Stoppers of Larimer County at 970-221-6868 or Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
